Showing results (91-100 of 142) with videos related to

Sort By:
Pageof 15
Blood Cancer Journal|October 24, 2020
Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 studyPaul G Richardson, Hans C Lee, Al-Ola Abdallah, et al.
Vaccine: X|April 6, 2023
COVID-19 vaccine uptake trends in SARS-CoV-2 previously infected cancer patientsZainab Shahid, Alicia L Patrick, Michelle L Wallander, et al.
The Lancet. Haematology|December 28, 2020
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trialSaad Z Usmani, Antje Hoering, Sikander Ailawadhi, et al.
Science (New York, N.Y.)|October 20, 2022
MTCH2 is a mitochondrial outer membrane protein insertaseAlina Guna, Taylor A Stevens, Alison J Inglis, et al.
Blood|February 29, 2008
Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagyQing Chen, Weilin Xie, Deborah J Kuhn, et al.
Science (New York, N.Y.)|April 13, 2023
Rethink reporting of evaluation results in AIRyan Burnell, Wout Schellaert, John Burden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2013
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman diseaseRazelle Kurzrock, Peter M Voorhees, Corey Casper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2022
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple MyelomaAnita D'Souza, Nina Shah, Cesar Rodriguez, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 1, 2023
A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First RelapseManisha Bhutani, David M Foureau, Myra Robinson, et al.
The Lancet. Oncology|November 17, 2018
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trialSuzanne Trudel, Nikoletta Lendvai, Rakesh Popat, et al.
Pageof 15